New Recruiting Trial: Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

WHY IT MATTERS

This trial offers patients with metastatic melanoma and liver involvement access to a novel combination therapy at a major academic medical center, potentially providing treatment options for a particularly aggressive cancer presentation.

Researchers at the University of Wisconsin are testing a new combination of two cancer treatments called Hepzato Kit and Opdualag for patients with melanoma (a type of skin cancer) that has spread to the liver. This is an early-stage study that started in 2026 and is currently looking for patients to participate. The goal is to see if this combination can help people whose cancer has spread to multiple parts of their body.

NCT ID: NCT07281924 Title: Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Status: RECRUITING Phase: PHASE1, PHASE2 Sponsor: University of Wisconsin, Madison Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07281924 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

If you have metastatic melanoma with liver involvement, contact the University of Wisconsin, Madison study team directly through ClinicalTrials.gov (NCT07281924) to ask about eligibility and enrollment.